Q3 2024

Filed Nov 12, 2024 · 10-Q · 43 days after period end · 0000950170-24-125388

Q3 2024 · 10-Q

Revenue

$123.00K

−99.7% vs Q3 2023

Net Income

-$17.08M

N/M vs Q3 2023

EPS Diluted

-$4.25

N/M vs Q3 2023

Operating Income-$47,692,000N/M

Operating Cash Flow

Same quarter

Metric	Q3 2024	Q3 2023	Q3 2022	Q3 2021
Revenue	$123.00K	$40.13M	$15.74M	$155.97M
Net Income	-$17.08M	-$63.62M	-$91.65M	$49.80M
EPS Diluted	-$4.25	-$0.65	-$0.98	$0.54

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Kyntra Bio, Inc. · CIK 921299 · Engraved from SEC EDGAR